

Identification of estrogen receptor-degrading autophagy-tethering chimera (ATTEC) lead compounds for treating patients with ER-positive breast cancer

Korea Research Institute of Chemical Technology



ONCOLOGY	Lead
Product Type	Other-TPD
Indication	Breast Cancer
Target	Estrogen Receptor
MoA(Mechanism of Action)	Autophagy Lysosomal Degradation
Competitiveness	<ul style="list-style-type: none">- Apply to ER-positive Breast Cancer Patients- Apply to Recurrent ER-positive Breast Cancer Patients- Apply to Chemo-resistant ER-positive Breast Cancer Patients
Development Stage	Lead identification
Route of Administration	IV, PO